145 related articles for article (PubMed ID: 12857569)
1. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.
Busca A; Locatelli F; Marmont F; Audisio E; Falda M
Haematologica; 2003 Jul; 88(7):837-9. PubMed ID: 12857569
[No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD).
Castagna L
Haematologica; 2003 Aug; 88(8):ELT28; author reply ELT29. PubMed ID: 12935991
[No Abstract] [Full Text] [Related]
3. Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.
Pohlreich D; Vitek A; Maalouf J; Cetkovsky P
Bone Marrow Transplant; 2006 Jan; 37(2):235-6; author reply 236-7. PubMed ID: 16284607
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient.
Basara N; Blau WI; Kiehl MG; Römer E; Rudolphi M; Bischoff M; Kirsten D; Sanchez H; Günzelmann S; Fauser AA
Transplant Proc; 1998 Dec; 30(8):4087-9. PubMed ID: 9865306
[No Abstract] [Full Text] [Related]
5. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation.
Hamilton BK; Bolwell B; Kalaycio M; Rybicki L; Hanna R; Sobecks R; Pohlman B; Andresen S; Dean R; Duong H; Hill B; Copelan E
Bone Marrow Transplant; 2013 Nov; 48(12):1578-80. PubMed ID: 23749105
[No Abstract] [Full Text] [Related]
6. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.
Basara N; Kiehl MG; Blau W; Römer E; Bischoff M; Schmetzer B; Kirsten D; Günzelmann S; Fauser AA
Transplant Proc; 2001 May; 33(3):2121-3. PubMed ID: 11377471
[No Abstract] [Full Text] [Related]
7. Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis.
Hamilton BK; Kalaycio M
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1869-70. PubMed ID: 25065905
[No Abstract] [Full Text] [Related]
8. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
Dvorak CC; Callard E; Agarwal R
Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
[No Abstract] [Full Text] [Related]
9. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Hattori K; Doki N; Kurosawa S; Hino Y; Yamamoto K; Sakaguchi M; Harada K; Ikegawa S; Shingai N; Senoo Y; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Ann Hematol; 2017 Feb; 96(2):319-321. PubMed ID: 27766393
[No Abstract] [Full Text] [Related]
11. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
12. Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis.
Okamura A; Shimoyama M; Ishii S; Wakahashi K; Asada N; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Katayama Y; Matsui T
Bone Marrow Transplant; 2011 Jan; 46(1):148-9. PubMed ID: 20228852
[No Abstract] [Full Text] [Related]
13. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation.
Menillo SA; Goldberg SL; McKiernan P; Pecora AL
Bone Marrow Transplant; 2001 Oct; 28(8):807-8. PubMed ID: 11781637
[No Abstract] [Full Text] [Related]
14. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients.
Kiehl MG; Schäfer-Eckart K; Kröger M; Bornhäuser M; Basara N; Blau IW; Kienast J; Fauser AA; Ehninger G; Armstrong VW; Shipkova M
Transplant Proc; 2002 Nov; 34(7):2922-4. PubMed ID: 12431658
[No Abstract] [Full Text] [Related]
15. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
16. The use of mycophenolate mofetil in liver transplant recipients.
Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of mycophenolate mofetil.
Basara N; Fauser AA
Bone Marrow Transplant; 2000 Dec; 26(12):1362-3. PubMed ID: 11223981
[No Abstract] [Full Text] [Related]
18. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
19. Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?
Levine JE
Pediatr Transplant; 2015 Sep; 19(6):582-3. PubMed ID: 26215797
[No Abstract] [Full Text] [Related]
20. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
